Effects on 24-hour intragastric pH:: A comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously

被引:39
作者
Freston, J
Chiu, YL
Pan, WJ
Lukasik, N
Täubel, J
机构
[1] Univ Connecticut, Ctr Hlth, Farmington, CT 06032 USA
[2] Abbott Labs, Abbott Pk, IL 60064 USA
[3] TAP Pharmaceut Prod, Lake Forest, IL USA
[4] Stamford Hosp, Charterhouse Clin Res Unit, London, England
关键词
D O I
10.1016/S0002-9270(01)02502-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVE: To compare the 24-h intragastric pH effects of lansoprazole, 30 mg administered nasogastrically, with pantoprazole, 40 mg administered i.v. METHODS: Healthy adults were enrolled in an open label, two-way crossover, single-center study. Thirty milligrams of lansoprazole (administered nasogastrically in apple juice) or pantoprazole (i.v.) were administered once daily at 8:00 AM for 5 consecutive days with at least a 2-wk washout period between the, regimens. Ambulatory 24-h intragastric pH was monitored at baseline and on days 1 and 5 of each treatment period. Blood specimens were collected on days 1 and 5 for pharmacokinetic parameter determinations. RESULTS: Thirty-three adults completed both crossover periods, with the exception of one patient with a zero lansoprazole plasma concentration on day 1 of period 2. Lansoprazole, 30 mg per nasogastric tube, produced significantly higher mean 24-h intragastric pH values relative to pantoprazole, 40 mg Lv., on both day 1 (3.05 vs 2.76, p < 0.002) and day 5 (3.65 vs 3.45, p = 0.024). Lansoprazole sustained the intragastric pH above 3 (days 1 and 5), 4, and 5 (day 1) significantly longer relative to pantoprazole. Lansoprazole's time to the maximum observed concentration and area under the plasma concentration-time curve over the 24-h time interval increased significantly from day 1 to day 5 (1.7 h vs 2.0 h and 1865 ng<bullet>h/ml vs 2091 ng .h/ml, respectively), and a significant increase in half-life relative to day 1 (0.96 h) was observed on day 5 (1.03 h) during pantoprazole treatment. CONCLUSION: Lansoprazole, 30 mg administered nasogastrically, effectively controls intragastric pH and is an alternative to i.v. pantoprazole in patients who are unable to swallow solid dosage formulations.
引用
收藏
页码:2058 / 2065
页数:8
相关论文
共 22 条
[1]  
BELL NJ, 1993, DIGESTION S1, V51, P59
[2]   Time to maximum effect of lansoprazole on gastric pH in normal male volunteers [J].
Bell, NJV ;
Hunt, RH .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (06) :897-904
[3]   The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion [J].
Blum, RA ;
Shi, H ;
Karol, MD ;
GreskiRose, PA ;
Hunt, RH .
CLINICAL THERAPEUTICS, 1997, 19 (05) :1013-1023
[4]   IS THERE AN OPTIMAL DEGREE OF ACID SUPPRESSION FOR HEALING OF DUODENAL-ULCERS - A MODEL OF THE RELATIONSHIP BETWEEN ULCER HEALING AND ACID SUPPRESSION [J].
BURGET, DW ;
CHIVERTON, SG ;
HUNT, RH .
GASTROENTEROLOGY, 1990, 99 (02) :345-351
[5]   Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis [J].
Chiba, N ;
DeGara, CJ ;
Wilkinson, JM ;
Hunt, RH .
GASTROENTEROLOGY, 1997, 112 (06) :1798-1810
[6]   LANSOPRAZOLE - AN ALTERNATIVE METHOD OF ADMINISTRATION OF A CAPSULE DOSAGE FORMULATION [J].
CHUN, AHC ;
EASON, CJ ;
SHI, HH ;
CAVANAUGH, JH .
CLINICAL THERAPEUTICS, 1995, 17 (03) :441-447
[7]   Lansoprazole: Administration of the contents of a capsule dosage formulation through a nasogastric tube [J].
Chun, AHC ;
Shi, HH ;
Achari, R ;
Dennis, S ;
Cavanaugh, JH .
CLINICAL THERAPEUTICS, 1996, 18 (05) :833-842
[8]   Lansoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion [J].
Dammann, HG ;
Fuchs, W ;
Richter, G ;
Burkhardt, F ;
Wolf, N ;
Walter, TA .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (02) :359-364
[9]  
DESVARANNES SB, 1994, ALIMENT PHARM THERAP, V8, P309
[10]   Twenty-four-hour monitoring of intragastric acidity: Comparison between lansoprazole 30mg and pantoprazole 40mg [J].
Florent, C ;
Forestier, S .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1997, 9 (02) :195-200